Post by Yelk on Jan 11, 2015 23:39:01 GMT
About ArQule
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule's lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company's pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase and ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR). ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent and selective against their targets.
-Cash and sec: $69 Million
-Outstanding: 62.8 Million
-PPS: $1.11 (All-time Low)
RE: November 20, 2014 Presentation: files.shareholder.com/downloads/ARQL/3825133010x0x795990/67d055be-1ca9-4971-a061-a359b06bd3f4/November%202014.pdf
Partnered lead program: Tivantinib first-in-class c-MET inhibitor:
-Pivotal Ph 3 clinical development in second line hepatocellular carcinoma (METIV-HCC trial) ongoing in western territories
-Independent Ph 3 clinical trial (JET-HCC) in second line HCC ongoing in Asia (Dec 2016)
Proprietary clinical pipeline: ARQ 092, ARQ 087 and ARQ 761
-Internally discovered/developed and fully owned
-Phase 1b clinical testing underway
-Financial position: sustainable into 2017:
-Strong cash balance funds proprietary pipeline development
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule's lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company's pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase and ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR). ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent and selective against their targets.
-Cash and sec: $69 Million
-Outstanding: 62.8 Million
-PPS: $1.11 (All-time Low)
RE: November 20, 2014 Presentation: files.shareholder.com/downloads/ARQL/3825133010x0x795990/67d055be-1ca9-4971-a061-a359b06bd3f4/November%202014.pdf
Partnered lead program: Tivantinib first-in-class c-MET inhibitor:
-Pivotal Ph 3 clinical development in second line hepatocellular carcinoma (METIV-HCC trial) ongoing in western territories
-Independent Ph 3 clinical trial (JET-HCC) in second line HCC ongoing in Asia (Dec 2016)
Proprietary clinical pipeline: ARQ 092, ARQ 087 and ARQ 761
-Internally discovered/developed and fully owned
-Phase 1b clinical testing underway
-Financial position: sustainable into 2017:
-Strong cash balance funds proprietary pipeline development
APRI up 150% and didn't do it either. 
